Group 1 - The core point of the article is that Shenzhen MicuRx Pharmaceuticals Co., Ltd. and Chengdu MicuRx Pharmaceuticals Co., Ltd. have initiated a Phase III clinical trial for the drug Xioroni in combination with PD-1 monoclonal antibody, albumin-bound paclitaxel, and gemcitabine for the first-line treatment of metastatic pancreatic ductal adenocarcinoma patients [1][2] - The clinical trial aims to evaluate the safety and tolerability of Xioroni in combination with chemotherapy during the induction phase, and the efficacy of the combination regimen during the randomized controlled phase [1] - The trial has a target enrollment of 558 participants and is currently ongoing, with the clinical trial registration number CTR20260141 and the first public information date set for January 15, 2026 [1][2] Group 2 - The primary endpoints of the trial include the incidence and severity of adverse events during the induction phase and overall survival (OS) during the randomized controlled phase [2] - Secondary endpoints encompass various measures such as objective response rate (ORR), duration of response (DoR), disease control rate (DCR), progression-free survival (PFS), and quality of life (QoL) assessments [2] - The drug Xioroni is a chemical medication indicated for metastatic pancreatic ductal adenocarcinoma, a malignancy characterized by high metastatic potential and poor prognosis [1][2]